Immunotherapy

Immunotherapy

Summary

immunotherapy is a therapeutic approach that modulates the immune system to produce anti-tumor effects, and in this entry it is used as a treatment context for outcome prediction and clinical evaluation. A clinician-deployable deep hypergraph model integrating clinical and CT radiomics predicted deep hypergraph for nsclc immunotherapy outcomes in NSCLC, highlighting a data-driven mechanism for patient stratification (PMID:42008547). In a phase I study, direct immunotherapy injection into oral precancer lesions was associated with tumor shrinkage and no dose-limiting toxicities, suggesting local delivery can be feasible and tolerable (PMID:42012894). Immunotherapy was also combined with targeted therapy and assessed for efficacy and safety in prostate cancer, indicating interest in combination regimens for advanced disease management (PMID:42017392). Overall, the provided studies span predictive modeling, local injection strategies, and combination therapy across lung, oral precancer, and prostate cancer settings.

Key Findings

NSCLC

  • A clinician-deployable deep hypergraph model integrating clinical and CT radiomics predicted immunotherapy outcomes in NSCLC, supporting outcome forecasting in a real-world treatment context (PMID:42008547).
  • The model specifically linked immunotherapy response prediction with a deep hypergraph architecture, implying multimodal feature integration for deep hypergraph for nsclc analysis (PMID:42008547).

Oral precancer

  • Direct immunotherapy injection into oral precancer lesions produced tumor shrinkage in a phase I clinical trial, indicating local therapeutic activity (PMID:42012894).
  • The trial reported no dose-limiting toxicities, supporting an initial safety signal for this delivery approach (PMID:42012894).
  • The study was published in 2026 in Cancer Discovery, underscoring recent translational progress in local immunotherapy delivery (PMID:42012894).

Prostate cancer

  • Immunotherapy combined with targeted therapy was evaluated for clinical benefit and safety in prostate cancer, reflecting a combination-treatment strategy (PMID:42017392).
  • The work focused on both efficacy and safety, suggesting assessment of tolerability alongside anti-tumor activity (PMID:42017392).
  • The study appeared in International Journal of Cancer in 2026, indicating ongoing clinical investigation of combination regimens (PMID:42017392).